The effects of benign prostatic hypertrophy (BPH) on the endothelin (ET) receptor density in the lower urinary tract tissues were studied using radioli-gand binding techniques. Saturation experiments revealed that there were significant amounts of the binding sites for the ET isoforms (ET-1, -2, -3) in the human bladder and prostate in both prostate hypertrophy (PH) and nonhypertrophy (NPH) patients. Autoradiograms of hypertrophic adenoma showed that ET-1 receptors were localized in both the stromal and glandular tissue. In the bladder and the prostate, the KD values were not significantly different between the PH and NPH groups. In the bladder dome, the Bmax values of 125I-ET-1, -2 and -3 decreased significantly in the PH groups, while, in the adenoma, they increased significantly in the PH group. BPH was found to affect the ET receptor density in both the bladder and the prostate. These data suggest that ETs are involved in the pathophysiology of BPH.

Keywords:
Endothelin receptor, Endothelin isoforms, Urinary bladder, Prostate, Benign prostatic hypertrophy
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.